Cargando…
A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971119/ https://www.ncbi.nlm.nih.gov/pubmed/35371643 http://dx.doi.org/10.7759/cureus.22717 |
_version_ | 1784679578285899776 |
---|---|
author | Ch, Saritha Sudha, Sree Reddy, C. Gowtham T, Pugazhenthan KSBS, Krishna Sasanka Dasari, Pooja Battula, Pradeep T, Nandini A, Sandeep |
author_facet | Ch, Saritha Sudha, Sree Reddy, C. Gowtham T, Pugazhenthan KSBS, Krishna Sasanka Dasari, Pooja Battula, Pradeep T, Nandini A, Sandeep |
author_sort | Ch, Saritha |
collection | PubMed |
description | Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression. Methodology The patients who were diagnosed with depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria were included in the study and were divided into two groups. The severity of depression in these patients was evaluated using Beck Depression Inventory and Hamilton depression scale (HAM-D) before and after the treatment (four weeks). Results About 64% of the study sample were males, and 36% were females, with 77% of the patients in the desvenlafaxine group taking 100 mg dosage and about 74% patients taking 50 mg dosage in the sertraline group. The patients in both groups showed statistically significant (p < 0.00001) improvement after using these drugs. Conclusion Both desvenlafaxine and sertraline showed their efficacy in treating depression by improving the clinical outcome in patients. Sertraline was marginally better in clinical results. Finally, it is advisable to carry out more randomized trials to improve the patient’s quality of life. |
format | Online Article Text |
id | pubmed-8971119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-89711192022-04-01 A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression Ch, Saritha Sudha, Sree Reddy, C. Gowtham T, Pugazhenthan KSBS, Krishna Sasanka Dasari, Pooja Battula, Pradeep T, Nandini A, Sandeep Cureus Neurology Background Depression is one of the most predominant mental health issues that are prevalent now. Therefore, many clinical trials were being conducted to find the safest, most effective, and tolerable anti-depressant. This study aims to compare desvenlafaxine and sertraline regarding their safety and efficacy in treating depression. Methodology The patients who were diagnosed with depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria were included in the study and were divided into two groups. The severity of depression in these patients was evaluated using Beck Depression Inventory and Hamilton depression scale (HAM-D) before and after the treatment (four weeks). Results About 64% of the study sample were males, and 36% were females, with 77% of the patients in the desvenlafaxine group taking 100 mg dosage and about 74% patients taking 50 mg dosage in the sertraline group. The patients in both groups showed statistically significant (p < 0.00001) improvement after using these drugs. Conclusion Both desvenlafaxine and sertraline showed their efficacy in treating depression by improving the clinical outcome in patients. Sertraline was marginally better in clinical results. Finally, it is advisable to carry out more randomized trials to improve the patient’s quality of life. Cureus 2022-02-28 /pmc/articles/PMC8971119/ /pubmed/35371643 http://dx.doi.org/10.7759/cureus.22717 Text en Copyright © 2022, Ch et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Neurology Ch, Saritha Sudha, Sree Reddy, C. Gowtham T, Pugazhenthan KSBS, Krishna Sasanka Dasari, Pooja Battula, Pradeep T, Nandini A, Sandeep A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression |
title | A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression |
title_full | A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression |
title_fullStr | A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression |
title_full_unstemmed | A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression |
title_short | A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression |
title_sort | comparative study on safety and efficacy of desvenlafaxine versus sertraline in depression |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971119/ https://www.ncbi.nlm.nih.gov/pubmed/35371643 http://dx.doi.org/10.7759/cureus.22717 |
work_keys_str_mv | AT chsaritha acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT sudhasree acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT reddycgowtham acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT tpugazhenthan acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT ksbskrishnasasanka acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT dasaripooja acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT battulapradeep acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT tnandini acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT asandeep acomparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT chsaritha comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT sudhasree comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT reddycgowtham comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT tpugazhenthan comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT ksbskrishnasasanka comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT dasaripooja comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT battulapradeep comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT tnandini comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression AT asandeep comparativestudyonsafetyandefficacyofdesvenlafaxineversussertralineindepression |